Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease
Kathleen E. Corey, Raj Vuppalanchi – 25 September 2012 – Watch a video presentation of this article
Impact of estimated liver volume and liver weight on gender disparity in liver transplantation
Ayse L. Mindikoglu, Sukru H. Emre, Laurence S. Magder – 24 September 2012 – Although lower Model for End‐Stage Liver Disease (MELD) scores due to lower levels of serum creatinine in women might account for some of the gender disparity in liver transplantation (LT) rates, even within MELD scores, women undergo transplantation at lower rates than men. It is unclear what causes this disparity, but transplant candidate/donor liver size mismatch may be a factor. We analyzed Organ Procurement and Transplantation Network data for patients with end‐stage liver disease on the waiting list.
Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction
Elisabeth R. Garwood, Nicholas Fidelman, Sarah E. Hoch, Robert K. Kerlan, Francis Y. Yao – 24 September 2012 – The purpose of this study was to determine the rate and risk factors for the development of irreversible hepatotoxicity after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and synthetic hepatic dysfunction. Two hundred fifty‐one consecutive patients with HCC and hepatic dysfunction who underwent 443 TACE procedures from 2005 to 2010 were retrospectively reviewed.
Interleukin‐28B polymorphism in hepatitis C and liver transplantation
Andres Duarte‐Rojo, Matthew G. Deneke, Michael R. Charlton – 24 September 2012 – The discovery of interleukin‐28B (IL‐28B) single‐nucleotide polymorphisms has opened an important new area of research in liver transplantation (LT) for hepatitis C virus (HCV).
Projected future increase in aging hepatitis C virus–infected liver transplant candidates: A potential effect of hepatocellular carcinoma
Scott W. Biggins, Kiran M. Bambha, Norah A. Terrault, John Inadomi, Stephen Shiboski, Jennifer L. Dodge, Jane Gralla, Hugo R. Rosen, John P. Roberts – 24 September 2012 – In the United States, the peak hepatitis C virus (HCV) antibody prevalence of 4% occurred in persons born in the calendar years 1940‐1965. The goal of this study was to examine observed and projected age‐specific trends in the demand for liver transplantation (LT) among patients with HCV‐associated liver disease stratified by concurrent hepatocellular carcinoma (HCC).
MicroRNA‐10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4‐Mediated epithelial‐mesenchymal transition and adhesion in hepatoma cells*
Yan Yan, Yue‐Chen Luo, Hai‐Ying Wan, Jun Wang, Pei‐Pei Zhang, Min Liu, Xin Li, Shengping Li, Hua Tang – 19 September 2012 – MicroRNAs (miRNAs) have been reported to be associated with the development of cancers. However, the function of miRNAs in human hepatocellular carcinoma (HCC) remains largely undefined. Here we found that overexpression of miR‐10a promoted the migration and invasion of QGY‐7703 and HepG2 cells in vitro but suppressed metastasis in vivo.
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry
Courtney Wilkins, Jessica Woodward, Daryl T.‐Y. Lau, Amy Barnes, Michael Joyce, Nicola McFarlane, Jane A. McKeating, D. Lorne Tyrrell, Michael Gale – 19 September 2012 – Type 1 interferon (IFN) continues to be the foundation for the current standard of care combination therapy for chronic hepatitis C virus (HCV) infection, yet the component interferon‐stimulated genes (ISGs) that mediate the antiviral actions of IFN are not fully defined.
Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era
Vivek N. Iyer, Karen L. Swanson, Rodrigo Cartin‐Ceba, Ross A. Dierkhising, Charles B. Rosen, Julie K. Heimbach, Russell H. Wiesner, Michael J. Krowka – 19 September 2012 – Hepatopulmonary syndrome (HPS) is a pulmonary vascular disorder occurring as a consequence of advanced liver disease, characterized by hypoxemia due to intrapulmonary vascular dilatations. HPS independently increases mortality, regardless of the cause or severity of liver disease. Liver transplantation (LT) improves survival in HPS.
Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes
Hacer Sahin, Erawan Borkham‐Kamphorst, Nicole T. do O, Marie‐Luise Berres, Michaela Kaldenbach, Petra Schmitz, Ralf Weiskirchen, Christian Liedtke, Konrad L. Streetz, Kathrin Maedler, Christian Trautwein, Hermann E. Wasmuth – 19 September 2012 – Aberrant expression of the chemokine CXC chemokine ligand (CXCL)10 has been linked to the severity of hepatitis C virus (HCV)‐induced liver injury, but the underlying molecular mechanisms remain unclear.
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis
Amy Dhirapong, Guo‐Xiang Yang, Steven Nadler, Weici Zhang, Koichi Tsuneyama, Patrick Leung, Stuart Knechtle, Aftab A. Ansari, Ross L. Coppel, Fu‐Tong Liu, Xiao‐Song He, M. Eric Gershwin – 19 September 2012 – Collectively, the data in both humans and murine models of human primary biliary cirrhosis (PBC) suggest that activated T cells, particularly CD8 T cells, play a critical role in biliary cell destruction.